Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292866350> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4292866350 abstract "Abstract Purpose Bevacizumab is important in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation. Bevacizumab biosimilar has received marketing approval based on the results of phase III clinical studies. It is the first retrospective study to verify the efficacy and safety of bevacizumab biosimilar in clinical application. Methods We identified 946 patients with locally advanced or metastatic NSCLC treated with bevacizumab biosimilar or bevacizumab. Efficacy evaluation was performed according to RECIST v1.1. Adverse events were graded following the CTCAE v5.0. Results The objective response rates (ORRs) were 28.9% in the biosimilar group (n=551) and 30.9% in the reference group (n=395; unstratified ORR risk ratio: 0.934, 95% confidence interval [CI]: 0.677–1.138). The estimated median progression-free survival (mPFS) were 6.27 (95% CI: 5.53–7.01) and 4.93 (95% CI: 4.24–5.62) months, respectively (p=0.296). The number of treatment lines, combined treatment regimens and with or without radiotherapy were significant factors affecting the PFS of both groups (p<0.001, p=0.001, p=0.039). Different genetic mutations and dose intensity were not the main factors (p=0.627, 0.946). The incidences of treatment-emergent adverse events (TEAEs) were 76.41% in the biosimilar group and 71.65% in the reference group (p=0.098). The incidences of grade 3 or higher TEAEs were 22.14% and 19.49%, respectively (p=0.324). Conclusion Bevacizumab biosimilar is equivalent in efficacy to bevacizumab in patients with locally advanced and advanced NSCLC. It showed acceptable toxicity profile and no new adverse events. Patients who were excluded by clinical trials can also benefit from bevacizumab biosimilar." @default.
- W4292866350 created "2022-08-24" @default.
- W4292866350 creator A5001569089 @default.
- W4292866350 creator A5006628326 @default.
- W4292866350 creator A5011827538 @default.
- W4292866350 creator A5013999534 @default.
- W4292866350 creator A5063300954 @default.
- W4292866350 creator A5066080633 @default.
- W4292866350 creator A5070654335 @default.
- W4292866350 creator A5073606490 @default.
- W4292866350 creator A5080456789 @default.
- W4292866350 date "2022-08-11" @default.
- W4292866350 modified "2023-10-14" @default.
- W4292866350 title "Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study" @default.
- W4292866350 cites W1505632988 @default.
- W4292866350 cites W2013335792 @default.
- W4292866350 cites W2115330744 @default.
- W4292866350 cites W2121500370 @default.
- W4292866350 cites W2125558775 @default.
- W4292866350 cites W2135140316 @default.
- W4292866350 cites W2510374213 @default.
- W4292866350 cites W2938851145 @default.
- W4292866350 cites W2942038781 @default.
- W4292866350 cites W2975389099 @default.
- W4292866350 cites W3011520922 @default.
- W4292866350 cites W3013347515 @default.
- W4292866350 cites W3030376148 @default.
- W4292866350 cites W3094019790 @default.
- W4292866350 cites W3121758283 @default.
- W4292866350 cites W3128646645 @default.
- W4292866350 cites W3180050323 @default.
- W4292866350 cites W4206841660 @default.
- W4292866350 cites W4210418069 @default.
- W4292866350 cites W4210992155 @default.
- W4292866350 cites W4223942141 @default.
- W4292866350 cites W4224223079 @default.
- W4292866350 doi "https://doi.org/10.21203/rs.3.rs-1943971/v1" @default.
- W4292866350 hasPublicationYear "2022" @default.
- W4292866350 type Work @default.
- W4292866350 citedByCount "1" @default.
- W4292866350 crossrefType "posted-content" @default.
- W4292866350 hasAuthorship W4292866350A5001569089 @default.
- W4292866350 hasAuthorship W4292866350A5006628326 @default.
- W4292866350 hasAuthorship W4292866350A5011827538 @default.
- W4292866350 hasAuthorship W4292866350A5013999534 @default.
- W4292866350 hasAuthorship W4292866350A5063300954 @default.
- W4292866350 hasAuthorship W4292866350A5066080633 @default.
- W4292866350 hasAuthorship W4292866350A5070654335 @default.
- W4292866350 hasAuthorship W4292866350A5073606490 @default.
- W4292866350 hasAuthorship W4292866350A5080456789 @default.
- W4292866350 hasBestOaLocation W42928663501 @default.
- W4292866350 hasConcept C126322002 @default.
- W4292866350 hasConcept C141071460 @default.
- W4292866350 hasConcept C143998085 @default.
- W4292866350 hasConcept C167135981 @default.
- W4292866350 hasConcept C197934379 @default.
- W4292866350 hasConcept C2776256026 @default.
- W4292866350 hasConcept C2776694085 @default.
- W4292866350 hasConcept C2777802072 @default.
- W4292866350 hasConcept C44249647 @default.
- W4292866350 hasConcept C59491497 @default.
- W4292866350 hasConcept C71924100 @default.
- W4292866350 hasConcept C90924648 @default.
- W4292866350 hasConceptScore W4292866350C126322002 @default.
- W4292866350 hasConceptScore W4292866350C141071460 @default.
- W4292866350 hasConceptScore W4292866350C143998085 @default.
- W4292866350 hasConceptScore W4292866350C167135981 @default.
- W4292866350 hasConceptScore W4292866350C197934379 @default.
- W4292866350 hasConceptScore W4292866350C2776256026 @default.
- W4292866350 hasConceptScore W4292866350C2776694085 @default.
- W4292866350 hasConceptScore W4292866350C2777802072 @default.
- W4292866350 hasConceptScore W4292866350C44249647 @default.
- W4292866350 hasConceptScore W4292866350C59491497 @default.
- W4292866350 hasConceptScore W4292866350C71924100 @default.
- W4292866350 hasConceptScore W4292866350C90924648 @default.
- W4292866350 hasLocation W42928663501 @default.
- W4292866350 hasOpenAccess W4292866350 @default.
- W4292866350 hasPrimaryLocation W42928663501 @default.
- W4292866350 hasRelatedWork W2387455091 @default.
- W4292866350 hasRelatedWork W2582613071 @default.
- W4292866350 hasRelatedWork W2597812774 @default.
- W4292866350 hasRelatedWork W2742486699 @default.
- W4292866350 hasRelatedWork W2883744750 @default.
- W4292866350 hasRelatedWork W2996348490 @default.
- W4292866350 hasRelatedWork W3046818137 @default.
- W4292866350 hasRelatedWork W3214898387 @default.
- W4292866350 hasRelatedWork W4296007264 @default.
- W4292866350 hasRelatedWork W4378640308 @default.
- W4292866350 isParatext "false" @default.
- W4292866350 isRetracted "false" @default.
- W4292866350 workType "article" @default.